CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2011, and company highlights. “To date in 2011, we have made solid progress in transforming Alnylam from a platform company to a product company focused on advancing RNAi therapeutic programs to patients. We currently have four programs in clinical development, which include ALN-TTR01 for the treatment of transthyretin-mediated amyloidosis and ALN-PCS for the treatment of severe hypercholesterolemia, both part of our ‘Alnylam 5x15’ product strategy,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.
